Atelvia FDA Approval History
Atelvia (risedronate sodium) is a bisphosphonate in a delayed-release formulation for treatment of postmenopausal osteoporosis.
Development Timeline for Atelvia
|Oct 11, 2010||ApprovalWarner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.